Petersen L-E, Kellermann MY, Schupp PJ. Secondary metabolites of marine microbes: from natural products chemistry to chemical ecology. In: Jungblut S, Liebich V, Bode-Dalby M, editors. YOUMARES 9—the oceans: our research, our future: proceedings of the 2018 conference for YOUng MArine RESearcher in Oldenburg, Germany. Cham: Springer International Publishing; 2020. p. 159–80. https://doi.org/10.1007/978-3-030-20389-4_8.
Kamyab E, Kellermann MY, Kunzmann A, Schupp PJ. Chemical Biodiversity and Bioactivities of Saponins in Echinodermata with an Emphasis on Sea Cucumbers (Holothuroidea). In: Jungblut S, Liebich V, Bode-Dalby M, editors. YOUMARES 9—the oceans: our research, our future: proceedings of the 2018 conference for YOUng MArine RESearcher in Oldenburg, Germany. Cham: Springer International Publishing; 2020. p. 121–57. https://doi.org/10.1007/978-3-030-20389-4_7
Gademann K, Kobylinska J. Antimalarial natural products of marine and freshwater origin. Chem Rec (New York, NY). 2009;9(3):187–98. https://doi.org/10.1002/tcr.200900001
Villa FA, Gerwick L. Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders. Immunopharmacol Immunotoxicol. 2010;32(2):228–37. https://doi.org/10.3109/08923970903296136
CAS Article PubMed Google Scholar
Bharate SB, Sawant SD, Singh PP, Vishwakarma RA. Kinase inhibitors of marine origin. Chem Rev. 2013;113(8):6761–815.
CAS Article PubMed Google Scholar
Zhang H, Zhao Z, Wang H. Cytotoxic natural products from marine sponge-derived microorganisms. Mar Drugs. 2017. https://doi.org/10.3390/md15030068.
Article PubMed PubMed Central Google Scholar
Chang YC, Tseng SW, Liu LL, Chou Y, Ho YS, Lu MC, Su JH. Cytotoxic sesterterpenoids from a sponge Hippospongia sp. Mar Drugs. 2012;10(5):987–97. https://doi.org/10.3390/md10050987
CAS Article PubMed PubMed Central Google Scholar
Wonganuchitmeta SN, Yuenyongsawad S, Keawpradub N, Plubrukarn A. Antitubercular sesterterpenes from the Thai sponge Brachiaster sp. J Nat Prod. 2004;67(10):1767–70. https://doi.org/10.1021/np0498354
CAS Article PubMed Google Scholar
Kamel HN, Kim YB, Rimoldi JM, Fronczek FR, Ferreira D, Slattery M. Scalarane sesterterpenoids: semisynthesis and biological activity. J Nat Prod. 2009;72(8):1492–6. https://doi.org/10.1021/np900326a
CAS Article PubMed Google Scholar
Yang YSH, Li ZL, Huang TY, Su KW, Lin CY, Huang CH, Chen HY, Lu MC, Huang HM, Lee SY, et al. Effect of estrogen on heteronemin-induced anti-proliferative effect in breast cancer cells with different estrogen receptor status. Front Cell Dev Biol. 2021;9:688607. https://doi.org/10.3389/fcell.2021.688607
Article PubMed PubMed Central Google Scholar
Huang CH, Huang TY, Chang WJ, Pan YS, Chu HR, Li ZL, Unson S, Chin YT, Lin CY, Huang HM, et al. Combined treatment of heteronemin and tetrac induces antiproliferation in oral cancer cells. Mar Drugs. 2020. https://doi.org/10.3390/md18070348.
Article PubMed PubMed Central Google Scholar
Chung CC, Huang TY, Chu HR, De Luca R, Candelotti E, Huang CH, Yang YSH, Incerpi S, Pedersen JZ, Lin CY, et al. Heteronemin and tetrac derivatives suppress non-small cell lung cancer growth via ERK1/2 inhibition. Food Chem Toxicol. 2022;161:112850. https://doi.org/10.1016/j.fct.2022.112850
CAS Article PubMed Google Scholar
Lee YS, Chin YT, Yang YSH, Wei PL, Wu HC, Shih A, Lu YT, Pedersen JZ, Incerpi S, Liu LF, et al. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status. Steroids. 2016;111:63–70. https://doi.org/10.1016/j.steroids.2016.03.006
CAS Article PubMed Google Scholar
Chang TC, Chin YT, Nana AW, Wang SH, Liao YM, Chen YR, Shih YJ, Changou CA, Yang YS, Wang K, et al. Enhancement by nano-diamino-tetrac of antiproliferative action of gefitinib on colorectal cancer cells: mediation by EGFR sialylation and PI3K activation. Horm Cancer. 2018;9(6):420–32. https://doi.org/10.1007/s12672-018-0341-x
Article PubMed PubMed Central Google Scholar
Huang TY, Chang TC, Chin YT, Pan YS, Chang WJ, Liu FC, Hastuti ED, Chiu SJ, Wang SH, Changou CA, et al. NDAT targets PI3K-mediated PD-L1 upregulation to reduce proliferation in gefitinib-resistant colorectal cancer. Cells. 2020. https://doi.org/10.3390/cells9081830.
Article PubMed PubMed Central Google Scholar
Chin YT, Wei PL, Ho Y, Nana AW, Changou CA, Chen YR, Yang YS, Hsieh MT, Hercbergs A, Davis PJ, et al. Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells. Endocr Relat Cancer. 2018;25(5):533–45. https://doi.org/10.1530/ERC-17-0376
CAS Article PubMed Google Scholar
Lee MG, Liu YC, Lee YL, El-Shazly M, Lai KH, Shih SP, Ke SC, Hong MC, Du YC, Yang JC, et al. Heteronemin, a marine sesterterpenoid-type metabolite, induces apoptosis in prostate lncap cells via oxidative and er stress combined with the inhibition of topoisomerase II and Hsp90. Mar Drugs. 2018. https://doi.org/10.3390/md16060204.
Article PubMed PubMed Central Google Scholar
Chen YC, Lu MC, El-Shazly M, Lai KH, Wu TY, Hsu YM, Lee YL, Liu YC. Breaking down leukemia walls: heteronemin, a sesterterpene derivative, induces apoptosis in leukemia molt4 cells through oxidative stress, mitochondrial dysfunction and induction of talin expression. Mar Drugs. 2018. https://doi.org/10.3390/md16060212.
Article PubMed PubMed Central Google Scholar
Wu JC, Wang CT, Hung HC, Wu WJ, Wu DC, Chang MC, Sung PJ, Chou YW, Wen ZH, Tai MH. Heteronemin is a novel c-Met/STAT3 inhibitor against advanced prostate cancer cells. Prostate. 2016;76(16):1469–83. https://doi.org/10.1002/pros.23230
CAS Article PubMed Google Scholar
Chen HL, Su YC, Chen HC, Su JH, Wu CY, Wang SW, Lin IP, Chen CY, Lee CH. Heteronemin suppresses lymphangiogenesis through ARF-1 and MMP-9/VE-Cadherin/Vimentin. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9091109.
Article PubMed PubMed Central Google Scholar
Bergonzini C, Kroese K, Zweemer AJM, Danen EHJ. Targeting integrins for cancer therapy—disappointments and opportunities. Front Cell Dev Biol. 2022. https://doi.org/10.3389/fcell.2022.863850/full.
Article PubMed PubMed Central Google Scholar
Li Q, Lan T, Xie J, Lu Y, Zheng D, Su B. Integrin-mediated tumorigenesis and its therapeutic applications. Front Oncol. 2022. https://doi.org/10.3389/fonc.2022.812480/full.
Article PubMed PubMed Central Google Scholar
Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY. Small molecule hormone or hormone-like ligands of integrin αVβ3: implications for cancer cell behavior. Horm Cancer. 2013;4(6):335–42. https://doi.org/10.1007/s12672-013-0156-8
CAS Article PubMed Google Scholar
Chin YT, He ZR, Chen CL, Chu HC, Ho Y, Su PY, Yang YSH, Wang K, Shih YJ, Chen YR, et al. Tetrac and NDAT induce anti-proliferation via integrin αvβ3 in colorectal cancers with different K-RAS status. Front Endocrinol (Lausanne). 2019;10:130. https://doi.org/10.3389/fendo.2019.00130.
Hay BA, Godugu K, Darwish NHE, Fujioka K, Sudha T, Karakus OO, Mousa SA. New thyrointegrin αvβ3 antagonist with a scalable synthesis, brain penetration, and potent activity against glioblastoma multiforme. J Med Chem. 2021;64(9):6300–9. https://doi.org/10.1021/acs.jmedchem.1c00350.
CAS Article PubMed Google Scholar
Darwish NHE, Glinsky GV, Sudha T, Mousa SA. Targeting thyrointegrin αvβ3 using fluorobenzyl polyethylene glycol conjugated tetraiodothyroacetic acid (NP751) in acute myeloid leukemia. Front Oncol. 2022. https://doi.org/10.3389/fonc.2021.793810.
Article PubMed PubMed Central Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. https://doi.org/10.3322/caac.20107.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. https://doi.org/10.3322/caac.21166.
Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34–45. https://doi.org/10.1038/35094009.
CAS Article PubMed Google Scholar
Nagle DG, Zhou YD. Marine natural products as inhibitors of hypoxic signaling in tumors. Phytochem Rev. 2009;8(2):415–29.
CAS Article PubMed PubMed Central Google Scholar
Kazlauskas R, Murphy PT, Quinn RJ, Wells RJ. Heteronemin, a new scalarin type sesterterpene from the sponge Heteronema Erecta. Tetrahedron Lett. 1976;17(30):2631–4. https://doi.org/10.1016/S0040-4039(00)91753-2.
Patil AD, Westley JW, Baures PW, Eggleston DS. Structure of heteronemin. Acta Crystallogr C. 1991;47(6):1250–3. https://doi.org/10.1107/S0108270190010915.
Kobayashi M, Okamoto T, Hayashi K, Yokoyama N, Sasaki T, Kitagawa I. Marine natural products. XXXII. Absolute configurations of C-4 of the manoalide family, biologically active sesterterpenes from the marine sponge Hyrtios erecta. Chem Pharm Bull (Tokyo). 1994;42(2):265–70. https://doi.org/10.1248/cpb.42.265.
CAS Article PubMed Google Scholar
Huang HH, Kuo SM, Wu YJ, Su JH. Improvement and enhancement of antibladder carcinoma cell effects of heteronemin by the nanosized hyaluronan aggregation. Int J Nanomedicine. 2016;11:1237–51. https://doi.org/10.2147/IJN.S99911.
CAS Article PubMed PubMed Central Google Scholar
Cheng MH, Huang HL, Lin YY, Tsui KH, Chen PC, Cheng SY, Chong IW, Sung PJ, Tai MH, Wen ZH, et al. BA6 induces apoptosis via stimulation of reactive oxygen species and inhibition of oxidative phosphorylation in human lung cancer cells. Oxid Med Cell Longev. 2019;2019:6342104. https://doi.org/10.1155/2019/6342104.
留言 (0)